TENNOR THERAP-B (06872) experienced a soaring movement intraday, with its stock price increasing by 105.55%. This significant price movement occurred during the morning trading session on a Friday.

The surge follows the company's highly anticipated initial public offering debut on the Hong Kong Stock Exchange. Investor demand was exceptionally strong, with the Hong Kong public offer being oversubscribed by 9,015.11 times and the international offering oversubscribed by 9.24 times. The IPO raised net proceeds of approximately HK$598 million, with cornerstone investments from reputable firms including AMR Action Fund, Hua Yuan International, and Orient Asset Management.

Market enthusiasm is driven by TenNor Therapeutics' promising pipeline of innovative drugs targeting bacterial infections. The company's core product, TNP-2198 (Lifotinezole), represents the first new molecular entity candidate globally targeting Helicobacter pylori infection since its discovery in 1982, with a New Drug Application submitted to Chinese regulators and expected approval by the end of 2026. Another key candidate, TNP-2092 injection (Lifotinezole), targets implant-related bacterial infections and is the world's first new molecular entity with potential efficacy against biofilm infections at clinically achievable doses.